



Name : Mr. DAVINDER BHASIN

Lab No. : 157573123

A/c Status

Age: 56 Years

SELF

Ref By:

Gender: Male

Collected Received : 20/12/2021 8:39:00AM

Received Reported

: 20/12/2021 9:44:12AM : 21/12/2021 8:03:58PM

Report Status : Final

Test Name Results Units Bio. Ref. Interval

SWASTHFIT TAX SAVER ADVANCE PACKAGE

| Hemoglobin | 15.40 | g/dL | 13.00 - 17.00 |
|------------------------------------|-------|----------|-----------------|
| Packed Cell Volume (PCV) | 48.10 | % | 40.00 - 50.00 |
| RBC Count | 5.59 | mill/mm3 | 4.50 - 5.50 |
| MCV | 86.00 | fL | 83.00 - 101.00 |
| MCH | 27.50 | pg | 27.00 - 32.00 |
| MCHC | 32.00 | g/dL | 31.50 - 34.50 |
| Red Cell Distribution Width (RDW) | 12.90 | % | 11.60 - 14.00 |
| Total Leukocyte Count (TLC) | 7.71 | thou/mm3 | 4.00 - 10.00 |
| Differential Leucocyte Count (DLC) | | | |
| Segmented Neutrophils | 62.70 | % | 40.00 - 80.00 |
| Lymphocytes | 26.80 | % | 20.00 - 40.00 |
| Monocytes | 6.70 | % | 2.00 - 10.00 |
| Eosinophils | 2.90 | % | 1.00 - 6.00 |
| Basophils | 0.90 | % | <2.00 |
| Absolute Leucocyte Count | | | |
| Neutrophils | 4.83 | thou/mm3 | 2.00 - 7.00 |
| Lymphocytes | 2.07 | thou/mm3 | 1.00 - 3.00 |
| Monocytes | 0.52 | thou/mm3 | 0.20 - 1.00 |
| Eosinophils | 0.22 | thou/mm3 | 0.02 - 0.50 |
| Basophils | 0.07 | thou/mm3 | 0.02 - 0.10 |
| Platelet Count | 273.0 | thou/mm3 | 150.00 - 410.00 |
| Mean Platelet Volume | 10.6 | fL | 6.5 - 12.0 |



Page 1 of 16



L38 - DEHRADUN LAB 2 HOME VISIT Dr. Lal Pathlabs Ltd 2nd Floor, No. 65, Ballupur-II Road, Cubic Tower, Chakrata

Name : Mr. DAVINDER BHASIN

: 157573123 Age: 56 Years

Ref By: SELF

Collected

: 20/12/2021 8:39:00AM

Received Reported

20/12/2021 9:44:12AM 21/12/2021 8:03:58PM

Report Status : Final

Pathizals Dr. Zat. Pathizals Dr. Zat. Pathizals

| Test Name | Results | Units | Bio. Ref. Interval |
|-----------|---------|-------|--------------------|
| ESR | 17 | mm/hr | 0.00 - 20.00 |
| | | | |

Gender:

Male

Note

Lab No.

A/c Status

- 1. As per the recommendation of International council for Standardization in Hematology, the differential leucocyte counts are additionally being reported as absolute numbers of each cell in per unit volume of blood
- 2. Test conducted on EDTA whole blood





L38 - DEHRADUN LAB 2 HOME VISIT Dr. Lai Pathlabs Ltd 2nd Floor, No. 65. Ballupur-II Road, Cubic Tower, Chakrata

: Mr. DAVINDER BHASIN

Collected

Male

Gender:

: 20/12/2021 8:39:00AM : 20/12/2021 9:44:12AM Received

Lab No. 157573123 A/c Status : P

Age: 56 Years

Ref By: SELF

Reported

: 21/12/2021 8:03:58PM

Report Status : Final

| Test Name | Results | Units | Bio. Ref. Interval |
|-----------------------------|---------|-------|--------------------|
| ALLERGY, PHADIATOP, ADULT** | 0.03 | kUA/L | <0.35 |
| (ImmunoCAP, FEIA) | | | |

Interpretation

| | REFERENCE RANGE IN kUA/L | REMARKS | |
|--|-----------------------------|--|----------------|
| | <0.35 | Negative - Indicates that symptoms are not caused by common environmental allergens. May require further testing. | |
| | >=0.35 | Positive - Indicates that patient is atopic. Higher values indicate higher degree of sensitization to common inhalant allergens. | |

Comments

This test differentiates between atopic & non-atopic diseases and comprises a balanced mixture of relevant allergens that react with specific IgE antibodies in the patient serum.

Atopy is a personal and / or familial tendency usually in childhood or adolescence to become sensitized and produce IgE antibodies in response to ordinary exposure to allergens. As a consequence these individuals can develop typical symptoms of Asthma, Rhinoconjunctivitis or Eczema.

| AMYLASE, SERUM | 37.49 | U/L | 28.00 - 100.00 |
|----------------|-------|-----|----------------|
| (PNP) | | | |

Comments

Amylase is produced in the Pancreas and most of the elevation in serum is due to increased rate of Amylase entry into the blood stream / decreased rate of clearance or both. Serum Amylase rises within 6 to 48 hours of onset of Acute pancreatitis in 80% of patients, but is not proportional to the severity of the disease. Activity usually returns to normal in 3-5 days in patients with milder edematous form of the disease. Values persisting longer than this period suggest continuing necrosis of pancreas or Pseudocyst formation. Approximately 20% of patients with Pancreatitis have normal or near normal activity. Hyperlipemic patients with Pancreatitis also spuriously normal Amylase levels due to suppression of Amylase activity by triglyceride. Low Amylase levels are seen in Chronic Pancreatitis, Congestive Heart failure, 2nd & 3rd trimesters of pregnancy, Gastrointestinal cancer & bone fractures.

| GLUCOSE, FASTING (F), PLASMA (Hexokinase) | 90.00 | mg/dL | 70.00 - 100.00 |
|---|-------|-------|----------------|
| CARDIO C-REACTIVE PROTEIN (hsCRP), SERUM** (Immunoturbidimetry) | 7.54 | mg/L | <1.00 |

Interpretation



Page 3 of 16





A/c Status : P

Name : Mr. DAVINDER BHASIN

Lab No. : 157573123 Age: 56 Years

Gender: Ma

Collected Received : 20/12/2021 8:39:00AM

Received Reported : 20/12/2021 9:44:12AM : 21/12/2021 8:03:58PM

Report Status : Final

Test Name Results Units Bio. Ref. Interval

| CARDIO CRP IN mg/L | CARDIOVASCULAR RISK |
|--------------------|---|
| <1 | Low |
| 1-3 | Average |
| 3-10 | нigh |
| >10 | Persistent elevation may represent Non cardiovascular inflammation |

Ref By: SELF

Note: To assess vascular risk, it is recommended to test hsCRP levels 2 or more weeks apart and calculate the average

Comments


High sensitivity C Reactive Protein (hsCRP) significantly improves cardiovascular risk assessment as it is a strongest predictor of future coronary events. It reveals the risk of future Myocardial infarction and Stroke among healthy men and women, independent of traditional risk factors. It identifies patients at risk of first Myocardial infarction even with low to moderate lipid levels. The risk of recurrent cardiovascular events also correlates well with hsCRP levels. It is a powerful independent risk determinant in the prediction of incident Diabetes.

| APOLIPOPROTEINS A1 & B, SERUM** (Immunoturbidimetry) | | | |
|--|------|-------|-----------------|
| Apolipoprotein (Apo A1)** | 82 | mg/dL | 105.00 - 175.00 |
| Apolipoprotein (Apo B)** | 74 | mg/dL | 60.00 - 140.00 |
| Apo B / Apo A1 Ratio** | 0.90 | | 0.35 - 0.98 |

Comments

Apolipoprotein B is a more powerful independent predictor of Coronary Heart Disease (CAD) than LDL Cholesterol. It is useful in assessing the risk of CAD and to classify Hyperlipidemias. Apolipoprotein studies help in monitoring coronary bypass surgery patients with regard to risk and severity of re-stenosis. They are also useful in assessing risk of re-infarction in patients of Myocardial infarction.

Apolipoprotein A1 is one of the apoproteins of high density lipoproteins (HDL) which is inversely related to the risk of CAD. Individuals with Tangier disease have < 1% of normal Apo A1. Levels <90mg/dL indicate increased risk of Atherosclerotic disease.



Page 4 of 16



L38 - DEHRADUN LAB 2 HOME VISIT Dr. Lal Pathlabs Ltd 2nd Floor, No. 65, Ballupur-II Road, Cubic Tower, Chakrata

Name : Mr. DAVINDER BHASIN

Collected

: 20/12/2021 8:39:00AM

Lab No. : 157573123

3123 Age: 56 Years

Received

: 20/12/2021 9:44:12AM

A/c Status P

Ref By : SELF

Reported

: 21/12/2021 8:03:58PM

Report Status : Final

Test Name Results Units Bio. Ref. Interval

Gender:

As per recommendations of National Cholesterol Education Program (NCEP) the clinical significance of results is as follows:

Apolipoprotein B

| | RESULT IN mg/dL | REMARKS |
|----|-----------------|---|
| | <23 | Abetalipoproteinemia/Hypobetalipoproteinemia |
| | 23-45 | Hypobetalipoproteinemia |
| | 46-135 | Normal |
| ¦_ | >135 | Hyperapobetalipoproteinemia/Increased CAD risk |

Apo B to A1 Ratio

| ļ | RATIO | REMARKS |
|---|-----------|-------------------------|
| | 0.35-0.98 | Desirable |
| | >0.98 | Increased CAD risk |

| IRON STUDIES, SERUM (Spectrophotometry) | | | |
|---|--------|-------|-----------------|
| Iron | 90.80 | μg/dL | 65.00 - 175.00 |
| Total Iron Binding Capacity (TIBC) | 357.80 | μg/dL | 250.00 - 425.00 |
| Transferrin Saturation | 25.38 | % | 20.00 - 50.00 |

Comments

Iron is an essential trace mineral element which forms an important component of hemoglobin, metallocompounds and Vitamin A. Deficiency of iron, leads to microcytic hypochromic anemia. The toxic effects of iron are deposition of iron in various organs of the body and hemochromatosis.

Total Iron Binding capacity (TIBC) is a direct measure of the protein Transferrin which transports iron from the gut to storage sites in the bone marrow. In iron deficiency anemia, serum iron is reduced and TIBC increases.

Transferrin Saturation occurs in Idiopathic hemochromatosis and Transfusional hemosiderosis where no unsaturated iron binding capacity is available for iron mobilization. Similar condition is seen in congenital deficiency of Transferrin.



Page 5 of 16



L38 - DEHRADUN LAB 2 HOME VISIT Dr. Lal Pathlabs Ltd 2nd Floor, No. 65. Ballupur-II Road, Cubic Tower, Chakrata

: Mr. DAVINDER BHASIN

Collected

: 20/12/2021 8:39:00AM

Lab No. : 157573123

Age: 56 Years

Received

: 20/12/2021 9:44:12AM

A/c Status : P

Ref By: SELF

Reported

: 21/12/2021 8:03:58PM

Report Status : Final

Test Name Results Units Bio. Ref. Interval 211.00 - 946.00 VITAMIN B12; CYANOCOBALAMIN, SERUM 217.70 pg/mL (ECLIA)

Gender:

Notes

- 1. Interpretation of the result should be considered in relation to clinical circumstances.
- 2. It is recommended to consider supplementary testing with plasma Methylmalonic acid (MMA) or plasma homocysteine levels to determine biochemical cobalamin deficiency in presence of clinical suspicion of deficiency but indeterminate levels. Homocysteine levels are more sensitive but MMA is more specific
- 3. False increase in Vitamin B12 levels may be observed in patients with intrinsic factor blocking antibodies, MMA measurement should be considered in such patients
- 4. The concentration of Vitamin B12 obtained with different assay methods cannot be used interchangeably due to differences in assay methods and reagent specificity

| VITAMIN D, 25 - HYDROXY, SERUM | 69.46 | nmol/L | 75.00 - 250.00 |
|--------------------------------|-------|--------|----------------|
| (ECLIA) | | | |

Interpretation

| LEVEL | REFERENCE RANGE IN nmol/L | COMMENTS |
|----------------------------------|--------------------------------|---|
| Deficient | < 50 | High risk for developing bone disease |
| Insufficient | 50-74 | Vitamin D concentration Which normalizes Parathyroid hormone concentration |
| Sufficient | 75-250 | Optimal concentration for maximal health benefit |
| Potential intoxication | >250 | High risk for toxic |

Note

- The assay measures both D2 (Ergocalciferol) and D3 (Cholecalciferol) metabolites of vitamin D.
- 25 (OH)D is influenced by sunlight, latitude, skin pigmentation, sunscreen use and hepatic function.
- Optimal calcium absorption requires vitamin D 25 (OH) levels exceeding 75 nmol/L.
- It shows seasonal variation, with values being 40-50% lower in winter than in summer.



Page 6 of 16



L38 - DEHRADUN LAB 2 HOME VISIT Dr. Lal Pathlabs Ltd 2nd Floor, No. 65, Ballupur-II Road, Cubic Tower, Chakrata

Name : Mr. DAVINDER BHASIN

Collected

: 20/12/2021 8:39:00AM

Lab No. : 157573123

157573123 Age: 56 Years

Male Received Reported

: 20/12/2021 9:44:12AM : 21/12/2021 8:03:58PM

A/c Status : P Ref By : SELF

Report Status : Final

Test Name Results Units Bio. Ref. Interval

Gender:

Levels vary with age and are increased in pregnancy.

• A new test Vitamin D, Ultrasensitive by LC-MS/MS is also available

Comments


Vitamin D promotes absorption of calcium and phosphorus and mineralization of bones and teeth. Deficiency in children causes Rickets and in adults leads to Osteomalacia. It can also lead to Hypocalcemia and Tetany. Vitamin D status is best determined by measurement of 25 hydroxy vitamin D, as it is the major circulating form and has longer half life (2-3 weeks) than 1,25 Dihydroxy vitamin D (5-8 hrs).

Decreased Levels


- Inadequate exposure to sunlight
- Dietary deficiency
- Vitamin D malabsorption
- · Severe Hepatocellular disease
- Drugs like Anticonvulsants
- Nephrotic syndrome

Increased levels

Vitamin D intoxication



Page 7 of 16





Name : Mr. DAVINDER BHASIN

Lab No. : 157573123 Age: 56 Years

A/c Status : P

ACAM DA ZAC PAMENTA DA EN

Ref By: SELF

Gender: Male

Collected

20/12/2021 8:39:00AM

Received Reported 20/12/2021 9:44:12AM 21/12/2021 8:03:58PM

Report Status : Final

| Test Name | Results | Units | Bio. Ref. Interval |
|------------------------------------|---------|-------|--------------------|
| LIVER & KIDNEY PANEL, SERUM | | | |
| Bilirubin Total (DPD) | 1.13 | mg/dL | 0.30 - 1.20 |
| Bilirubin Direct (DPD) | 0.25 | mg/dL | <0.30 |
| Bilirubin Indirect (Calculated) | 0.88 | mg/dL | <1.10 |
| AST (SGOT) (IFCC without P5P) | 23 | U/L | <50 |
| ALT (SGPT) (IFCC without P5P) | 39 | U/L | <50 |
| GGTP (GCNA) | 25 | U/L | <55 |
| Alkaline Phosphatase (ALP) (PNPP) | 104 | U/L | 30 - 120 |
| Total Protein (Biuret) | 7.92 | g/dL | 6.40 - 8.30 |
| Albumin (BCG) | 4.55 | g/dL | 3.50 - 5.20 |
| A : G Ratio (Calculated) | 1.35 | | 0.90 - 2.00 |
| Urea (Urease UV) | 23.90 | mg/dL | 17.00 - 43.00 |
| Creatinine (Modified Jaffe) | 1.00 | mg/dL | 0.67 - 1.17 |
| Uric Acid (Uricase) | 8.52 | mg/dL | 3.50 - 7.20 |
| I | | | |



Page 8 of 16



L38 - DEHRADUN LAB 2 HOME VISIT Dr. Lal Pathlabs Ltd 2nd Floor, No. 65, Ballupur-Il Road, Cubic Tower, Chakrata

Name : Mr. DAVINDER BHASIN

Lab No. : 157573123 Age: 56 Years

A/c Status : P Ref By : SELF

Collected

20/12/2021 8:39:00AM

Received Reported 20/12/2021 9:44:12AM 21/12/2021 8:03:58PM

Report Status :

: Final

| Test Name Calcium, Total (Arsenazo III) | Results 9.88 | Units mg/dL | Bio. Ref. Interval 8.80 - 10.60 |
|---|-----------------|-----------------------|--|
| Phosphorus (Molybdate UV) | 3.92 | mg/dL | 2.40 - 4.40 |
| Sodium (Indirect ISE) | 138.00 | mEq/L | 136.00 - 146.00 |
| Potassium (Indirect ISE) | 4.99 | mEq/L | 3.50 - 5.10 |
| Chloride (Indirect ISE) | 101.10 | mEq/L | 101.00 - 109.00 |

Male

Gender:







Name : Mr. DAVINDER BHASIN

Collected

: 20/12/2021 8:39:00AM

Lab No. ;

157573123

Gender:

Male

Received Reported : 20/12/2021 9:44:12AM : 21/12/2021 8:03:58PM

A/c Status : P

Do Lat i

Age: 56 Years
Ref By: SELF


Report Status

: Final

| Test Name | Results | Units | Bio. Ref. Interval |
|--|-------------------|-------|----------------------------|
| URINE EXAMINATION, ROUTINE; URINE, R/E | | | |
| (Dipstick, Microscopy) | | | |
| Physical | | | |
| Colour | Light Yellow | | Pale yellow |
| Specific Gravity | 1.020 | | 1.001 - 1.030 |
| pH | 6.5 | | 5.0 - 8.0 |
| Chemical | | | |
| Proteins | Negative | | Negative |
| Glucose | Negative | | Negative |
| Ketones | Negative | | Negative |
| Bilirubin | Negative | | Negative |
| Urobilinogen | Negative | | Negative |
| Leucocyte Esterase | Negative | | Negative |
| Nitrite | Negative | | Negative |
| Microscopy | | | |
| R.B.C. | Negative | | 0.0 - 2.0 RBC/hpf |
| Pus Cells | 0-1 WBC/HPF | | 0-5 WBC / hpf |
| Epithelial Cells | 0-1 Epi Cells/hpf | | 0.0 - 5.0 Epi cells/hpf |
| Casts | None seen | | None seen/Lpf |
| Crystals | None seen | | None seen |
| Others | None seen | | None seen |

Page 10 of 16





Ballupur-II Road, Cubic Tower, Chakrata

Name Mr. DAVINDER BHASIN

Lab No. 157573123

Age: 56 Years

Ref By:

SELF

Gender:

Male

Collected Received

Web: www.lalpathlabs.com, CIN No.: L74899DL1995PLC065388

20/12/2021 8:39:00AM 20/12/2021 9:44:12AM

Reported 21/12/2021 8:03:58PM

: Final **Report Status**

| Results | Units | Bio. Ref. Interval |
|---------|-------|--------------------|
| | | |
| 5.8 | % | 4.00 - 5.60 |
| 120 | mg/dL | |
| | 5.8 | 5.8 % |

Interpretation

A/c Status

HbA1c result is suggestive of at risk for Diabetes (Prediabetes)/ well controlled Diabetes in a known Diabetic

Note: Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered, particularly when the HbA1C result does not correlate with the patient's blood glucose levels.

| FACTORS THAT INTERFERE WITH HbA1C MEASUREMENT | FACTORS THAT AFFECT INTERPRETATION OF HBA1C RESULTS |
|--|---|
| Hemoglobin variants, elevated fetal hemoglobin (HbF) and chemically modified derivatives of hemoglobin (e.g. carbamylated Hb in patients with renal failure) can affect the accuracy of HbAlc measurements | Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g.,recovery from acute blood loss, hemolytic anemia, HbSS, HbCC, and HbSC) will falsely lower HbA1c test results regardless of the assay method used.Iron deficiency anemia is associated with higher HbA1c |







Name : Mr. DAVINDER BHASIN

Lab No. : 157573123

A/c Status

Ref By: SELF

Age: 56 Years

Collected Received : 20/12/2021 8:39:00AM

Received Reported 20/12/2021 9:44:12AM 21/12/2021 8:03:58PM

Report Status

atus : Final

| Test Name | Results | Units | Bio. Ref. Interval |
|--------------------------------------|---------|--------|--------------------|
| THYROID PROFILE,TOTAL, SERUM (ECLIA) | | | |
| T3, Total | 0.81 | ng/mL | 0.80 - 2.00 |
| T4, Total | 7.16 | μg/dL | 5.10 - 14.10 |
| TSH | 2.13 | μIU/mL | 0.27 - 4.20 |

Gender:

Male

Note

- 1. TSH levels are subject to circadian variation, reaching peak levels between 2 4.a.m. and at a minimum between 6-10 pm . The variation is of the order of 50% . hence time of the day has influence on the measured serum TSH concentrations.
- 2. Alteration in concentration of Thyroid hormone binding protein can profoundly affect Total T3 and/or Total T4 levels especially in pregnancy and in patients on steroid therapy.
- 3. Unbound fraction (Free,T4 /Free,T3) of thyroid hormone is biologically active form and correlate more closely with clinical status of the patient than total T4/T3 concentration
- 4. Values <0.03 uIU/mL need to be clinically correlated due to presence of a rare TSH variant in some individuals



Page 12 of 16



L38 - DEHRADUN LAB 2 HOME VISIT Dr. Lal Pathlabs Ltd 2nd Floor, No. 65. Ballupur-II Road, Cubic Tower, Chakrata

Name : Mr. DAVINDER BHASIN

Lab No. : 157573123

A/c Status

Age: 56 Years

Ref By: SELF

Gender: Male Collected Received 20/12/2021 8:39:00AM

Reported

20/12/2021 9:44:12AM 21/12/2021 8:03:58PM

Report Status

| Test Name | Results | Units | Bio. Ref. Interval |
|--|---------|-------|--------------------|
| LIPID SCREEN, SERUM (Spectrophotometry) | | | |
| Cholesterol, Total | 126.00 | mg/dL | <200.00 |
| Triglycerides | 80.00 | mg/dL | <150.00 |
| HDL Cholesterol | 36.00 | mg/dL | >40.00 |
| LDL Cholesterol, Calculated | 74.00 | mg/dL | <100.00 |
| VLDL Cholesterol,Calculated | 16.00 | mg/dL | <30.00 |
| Non-HDL Cholesterol | 90 | mg/dL | <130 |
| | | | |

Interpretation

| REMARKS | TOTAL CHOLESTEROL in mg/dL | TRIGLYCERIDE in mg/dL | LDL CHOLESTEROL in mg/dL | NON HDL CHOLESTEROL in mg/dL |
|-----------------|---------------------------------|--------------------------|-------------------------------|-------------------------------------|
| Optimal | <200 | <150 | <100 | <130 |
| Above Optimal | _ | _ | 100-129 | 130 - 159 |
| Borderline High | 200-239 | 150-199 | 130-159 | 160 - 189 |
| High | >=240 | 200-499 | 160-189 | 190 - 219 |
| Very High | - | >=500 | >=190 | >=220 |

Note

- 1. Measurements in the same patient can show physiological & analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL& LDL Cholesterol.
- 2. NLA-2014 recommends a complete lipoprotein profile as the initial test for evaluating cholesterol.
- 3. Friedewald equation to calculate LDL cholesterol is most accurate when Triglyceride level is < 400 mg/dL. Measurement of Direct LDL cholesterol is recommended when Triglyceride level is > 400 mg/dL



Page 13 of 16



L38 - DEHRADUN LAB 2 HOME VISIT Dr. Lal Pathlabs Ltd 2nd Floor, No. 65, Ballupur-II Road, Cubic Tower, Chakrata

Name : Mr. DAVINDER BHASIN

Collected

20/12/2021 8:39:00AM

Lab No. :

: 157573123 Age: 56 Years

Received Reported

20/12/2021 9:44:12AM 21/12/2021 8:03:58PM

A/c Status : P Ref By : SELF

Report Status

: Final

Test Name Results Units Bio. Ref. Interval

Male

 NLA-2014 identifies Non HDL Cholesterol(an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants)along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDI

Gender:

- 5. Apolipoprotein B is an optional, secondary lipid target for treatment once LDL & Non HDL goals have been achieved
- 6. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

Treatment Goals as per Lipid Association of India 2016

| RISK | TREATMENT GOAL | | CONSIDER THERAPY | |
|-------------------|--------------------------------|--|-----------------------------------|--|
| CATEGORY | LDL CHOLESTEROL (LDL-C)(mg/dL) | NON HDL CHLOESTEROL (NON HDL-C) (mg/dL) | LDL CHOLESTEROL (LDL-C)(mg/dL) | NON HDL CHLOESTEROL (NON HDL-C) (mg/dL) |
| Very High | <50 | <80 | >=50 | >=80 |
| High | | <100 | >=70 | >=100 |
| Moderate | <100 | <130 | >=100 | >=130 |
| Low | <100 | <130 | >=130* | >=160* |

^{*}In low risk patient, consider therapy after an initial non-pharmacological intervention for at least 3 months



Page 14 of 16



L38 - DEHRADUN LAB 2 HOME VISIT Dr. Lal Pathlabs Ltd 2nd Floor, No. 65, Ballupur-II Road, Cubic Tower, Chakrata

Name : Mr. DAVINDER BHASIN

Lab No. : 157573123

573123 Age: 56 Years

Ref By: SELF

Gender: Male

Received Reported

: 20/12/2021 8:39:00AM : 20/12/2021 9:44:12AM

: 21/12/2021 8:03:58PM

Report Status : Final

Test Name

A/c Status

Dr Ajay Gupta MD, Pathology Technical Director - Hematology &

Immunology NRL - Dr Lal PathLabs Ltd Results

Units

Bio. Ref. Interval

Jahm

Dr Jatin Munjal MD,Pathology Consultant Pathologist Dr Lal PathLabs Ltd Dr.Kamal Modi MD, Biochemistry Consultant Biochemist NRL - Dr Lal PathLabs Ltd

of kunst

Dr Nimmi Kansal MD, Biochemistry Technical Director - Clinical Chemistry & Biochemical Genetics NRL - Dr Lal PathLabs Ltd Jel

Dr Pritika Uniyal MD, Pathology Chief of Lab

MD, Biochemistry

Sr. Consultant Biochemist

NRL - Dr Lal PathLabs Ltd

Sariti Kumari la

Dr Sarita Kumari Lal MD, Pathology Consultant Pathologist Dr Lal PathLabs Ltd

Dr Sunanda MD, Pathology

Consultant Pathologist Dr Lal PathLabs Ltd

-----End of report



** Test conducted under NABL scope MC-2113,LPL-NATIONAL REFERENCE LAB at NEW DELHI

Page 15 of 16



L38 - DEHRADUN LAB 2 HOME VISIT Dr. Lal Pathlabs Ltd 2nd Floor, No. 65, Ballupur-II Road, Cubic Tower, Chakrata

Name : Mr. DAVINDER BHASIN

Lab No.

A/c Status

THOER DITAON at Pathilada De Lat Pathilada De Lat Pathilada De

: 157573123 Age: 56 Years Gender: Male

Ref By: SELF

Collected : 20/12/2021 8:39:00AM Received : 20/12/2021 9:44:12AM

Reported : 21/12/2021 8:03:58PM

Report Status : Final

Test Name Results Units Bio. Ref. Interval

IMPORTANT INSTRUCTIONS

•Test results released pertain to the specimen submitted. •All test results are dependent on the quality of the sample received by the Laboratory. •Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician. •Sample repeats are accepted on request of Referring Physician within 7 days post reporting. •Report delivery may be delayed due to unforeseen circumstances. Inconvenience is regretted. •Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit request within 72 hours post reporting. •Test results may show interlaboratory variations. •The Courts/Forum at Delhi shall have exclusive jurisdiction in all disputes/claims concerning the test(s) & or results of test(s). •Test results are not valid for medico legal purposes. •Contact customer care Tel No. +91-11-39885050 for all queries related to test results.



Page 16 of 16